Report Detail

North America, the colorectal cancer market, is anticipated to reach US$ 10,655.1 Mn in 2027 from US$ 7,691.4 Mn in 2019. The market is projected to grow with a CAGR of 4.2% from 2020-2027.

The colorectal cancer market is growing primarily due to the increasing prevalence of colorectal cancer, new product launches, and benefits offered by generic drugs that are boosting the market over the years. Restraining factors, such as pricing pressure on drug manufacturers, are likely to damage the growth of the market in the coming years. On the other hand, growing R&D expenditure for cancer research is expected to have a positive impact on the growth of the North American colorectal cancer market in the coming years.

Colorectal cancer is also known as colon cancer, bowel cancer, or rectal cancer. This type of cancer is the second leading cause of death in women and third in men. Colorectal cancer may be benign, or non-cancerous, or malignant. The symptoms shown by the patients who have colon cancer include changes in bowel habits, diarrhea or constipation, blood in stools that make it look black. Colorectal cancer can be treated with chemotherapy, radiotherapy, and surgery.

Colorectal cancer is one of the commonly found and lethal cancers which is developed in an individual with the combined influence of genetic and environmental factors. Additionally, according to the World Health Organization (WHO), colorectal cancer was the third most prevalent form of cancers, with approximately 1.80 million cases around the world in 2018, excluding skin cancer. The rates of colorectal cancer mortality and incidence vary across the globe as per the reports by WHO’s cancer database GLOBOCAN. The GLOBOCAN reports approximately 861,000 deaths in 2018 due to colorectal cancer. The data released by the Canadian Cancer Society in 2019, around 1 in 14 Canadian men will be diagnosed with colorectal cancer during their lifetime, and 1 in 18 Canadian women will be diagnosed with colorectal cancer during their lifetime and. Thus, the rising number of patients suffering from the disease is likely to drive the growth of colorectal cancer during the forecast period.
In 2019, the diagnosis type accounted for the largest market share in the North American colorectal cancer market. The growth of diagnosis type is expected to grow due to rising colorectal screening programs and initiatives across the world. The diagnosis type segment is also estimated to mark the highest CAGR in the market during the forecast period, owing to the increasing technological development that is enabling the early detection of colorectal cancer by the various method of screenings.
In 2019, the hospitals segment held the most significant market share of the colorectal cancer market by the end user. This segment is also anticipated to hold a considerable portion of the market in 2027, owing to the need for hospitals as primary healthcare centers for the people. The segment is also anticipated to witness growth at a significant rate during the forecast period.
Some of the significant primary and secondary sources for colorectal cancer included in the report are World Health Organization (WHO), Food and Drug Administration (FDA), Canadian Cancer Society, Centers for Disease Control and Prevention (CDC), American Cancer Society and others.


TABLE OF CONTENTS

    1. Introduction

    • 1.1 Scope of the Study
    • 1.2 The Insight Partners Research Report Guidance
    • 1.3 Market Segmentation
      • 1.3.1 North America colorectal cancer Market – By Modality
      • 1.3.2 North America colorectal cancer Market – By End User
      • 1.3.3 North America colorectal cancer Market – By Country

    2. North America Colorectal Cancer Market – Key Takeaways

      3. Research Methodology

      • 3.1 Coverage
      • 3.2 Secondary Research
      • 3.3 Primary Research

      4. North America Colorectal Cancer Market – Market Landscape

      • 4.1 overview
      • 4.2 PEST Analysis
        • 4.2.1 Colorectal Cancer Market - North America PEST Analysis
      • 4.3 Expert Opinion

      5. North America Colorectal Cancer Market - Key Market Dynamics

      • 5.1 Key Market Drivers
        • 5.1.1 Increasing Prevalence Of Colorectal Cancer
        • 5.1.2 New Product Launches
        • 5.1.3 Benefits Offered By Generic Drugs
      • 5.2 Key Restraints
        • 5.2.1 Pricing Pressure On Drug Manufacturers
      • 5.3 Key Market Opportunities
        • 5.3.1 Growing R&D Expenditure for Cancer Research
      • 5.4 Future Trend
        • 5.4.1 Inclination Towards Personalized Medicine
      • 5.5 Impact Analysis

      6. Colorectal Cancer Market – North America Analysis

      • 6.1 North America Colorectal Cancer Market Revenue Forecasts and Analysis
      • 6.2 Positioning Of Key Players

      7. North America Colorectal Cancer Market Analysis And Forecasts To 2027 – Modality

      • 7.1 Overview
      • 7.2 North America Colorectal Cancer Market, By Modality 2018 & 2027 (%)
        • 7.2.1 North America Colorectal Cancer Market Revenue and Forecasts to 2027, By Modality (US$ Mn)
          • 7.2.1.1 North America Diagnosis Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
          • 7.2.1.2 North America Therapy Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
          • 7.2.1.2.1 North America Chemotherapy Market Revenue and Forecasts to 2027, By Type (US$ Mn)
          • 7.2.1.2.2 North America Immunotherapy Market Revenue and Forecasts to 2027, By Type (US$ Mn)
          • 7.2.1.3 North America Imaging Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
      • 7.3 Diagnosis Type Market
        • 7.3.1 Overview
        • 7.3.2 North America Diagnosis Type Market Revenue and Forecast to 2027 (US$ Mn)
        • 7.3.3 Immunohistochemistry Market
          • 7.3.3.1 Overview
          • 7.3.3.2 North America Immunohistochemistry Market Revenue and Forecast to 2027 (US$ Mn)
        • 7.3.4 Stool Test Market
          • 7.3.4.1 Overview
          • 7.3.4.2 North America Stool Test Market Revenue and Forecast to 2027 (US$ Mn)
        • 7.3.5 Flexible Sigmoidoscopy Market
          • 7.3.5.1 Overview
          • 7.3.5.2 North America Flexible Sigmoidoscopy Market Revenue and Forecast to 2027 (US$ Mn)
        • 7.3.6 Colonoscopy Market
          • 7.3.6.1 Overview
          • 7.3.6.2 North America Colonoscopy Market Revenue and Forecast to 2027 (US$ Mn)
        • 7.3.7 CEA Test Market
          • 7.3.7.1 Overview
          • 7.3.7.2 North America CEA Test Market Revenue and Forecast to 2027 (US$ Mn)
        • 7.3.8 Other Test Market
          • 7.3.8.1 Overview
          • 7.3.8.2 North America Other Test Market Revenue and Forecast to 2027 (US$ Mn)
      • 7.4 Therapy Type Market
        • 7.4.1 Overview
        • 7.4.2 North America Therapy Type Market Revenue and Forecasts to 2027 (US$ Mn)
        • 7.4.3 Chemotherapy Market
          • 7.4.3.1 Overview
          • 7.4.3.2 North America Chemotherapy Market Revenue and Forecast to 2027 (US$ Mn)
          • 7.4.3.3 Alkylating Agent Market
          • 7.4.3.3.1 Overview
          • 7.4.3.3.2 North America Alkylating Agent Market Revenue and Forecast to 2027 (US$ Mn)
          • 7.4.3.4 Antimetabolites Market
          • 7.4.3.4.1 North America Antimetabolites Market Revenue and Forecast to 2027 (US$ Mn)
          • 7.4.3.5 Others Market
          • 7.4.3.5.1 North America Others Market Revenue and Forecast to 2027 (US$ Mn)
          • 7.4.4 Immunotherapy Market
            • 7.4.4.1 Overview
            • 7.4.4.2 North America Immunotherapy Market Revenue and Forecast to 2027 (US$ Mn)
            • 7.4.4.3 Panitumumab Market
            • 7.4.4.3.1 Overview
            • 7.4.4.3.2 North America Panitumumab Market Revenue and Forecast to 2027 (US$ Mn)
            • 7.4.4.4 Cetuximab Market
            • 7.4.4.4.1 Overview
            • 7.4.4.4.2 North America Cetuximab Market Revenue and Forecast to 2027 (US$ Mn)
            • 7.4.4.5 Bevacizumab Market
            • 7.4.4.5.1 Overview
            • 7.4.4.5.2 North America Bevacizumab Market Revenue and Forecast to 2027 (US$ Mn)
            • 7.4.4.6 Others Market
            • 7.4.4.6.1 Overview
            • 7.4.4.6.2 North America Others Market Revenue and Forecast to 2027 (US$ Mn)
            • 7.4.5 Chemoprotectant Market
              • 7.4.5.1 Overview
              • 7.4.5.2 North America Chemoprotectant Market Revenue and Forecast to 2027 (US$ Mn)
            • 7.4.6 Others Market
              • 7.4.6.1 Overview
              • 7.4.6.2 North America Others Market Revenue and Forecast to 2027 (US$ Mn)
          • 7.5 Imaging Type Market
            • 7.5.1 Overview
            • 7.5.2 North America Imaging Type Market Revenue and Forecasts to 2027 (US$ Mn)
            • 7.5.3 Computed Tomography (CT) Market
              • 7.5.3.1 Overview
              • 7.5.3.2 North America Computed Tomography (CT) Market Revenue and Forecast to 2027 (US$ Mn)
            • 7.5.4 Magnetic Resonance Imaging (MRI) Market
              • 7.5.4.1 Overview
              • 7.5.4.2 North America Magnetic Resonance Imaging (MRI) Market Revenue and Forecast to 2027 (US$ Mn)
            • 7.5.5 Others Market
              • 7.5.5.1 Overview
              • 7.5.5.2 North America Others Market Revenue and Forecast to 2027 (US$ Mn)

            8. North America Colorectal Cancer Market Analysis– By End User

            • 8.1 Overview
            • 8.2 North America Colorectal Cancer Market, By End User 2018 & 2027 (%)
              • 8.2.1 North America Colorectal Cancer Market Revenue and Forecasts to 2027, By End User (US$ Mn)
            • 8.3 Hospitals Market
              • 8.3.1 Overview
              • 8.3.2 North America Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 8.4 Diagnostic and Research Laboratories Market
              • 8.4.1 Overview
              • 8.4.2 North America Diagnostic and Research Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

            9. Colorectal Cancer Market Revenue And Forecasts To 2027 – Geographical Analysis

            • 9.1 North America Colorectal Cancer Market Revenue and Forecasts To 2027
              • 9.1.1 Overview
              • 9.1.2 North America Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
              • 9.1.3 North America Colorectal Cancer Market Revenue and Forecasts to 2027, By Modality (US$ Mn)
                • 9.1.3.1 North America Diagnosis Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.3.2 North America Therapy Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.3.2.1 North America Chemotherapy Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.3.2.2 North America Immunotherapy Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.3.3 North America Imaging Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
              • 9.1.4 North America Colorectal Cancer Market Revenue and Forecasts to 2027, By End User (US$ Mn)
              • 9.1.5 North America Colorectal Cancer Market Revenue and Forecasts to 2027, By Country (%)
              • 9.1.6 US Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
                • 9.1.6.1 US Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
                • 9.1.6.2 US Colorectal Cancer Market Revenue and Forecasts to 2027, By Modality (US$ Mn)
                • 9.1.6.2.1 US Diagnosis Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.6.2.2 US Therapy Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.6.2.3 US Imaging Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.6.3 US Colorectal Cancer Market Revenue and Forecasts to 2027, By End User (US$ Mn)
              • 9.1.7 Canada Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
                • 9.1.7.1 Canada Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
                • 9.1.7.2 Canada Colorectal Cancer Market Revenue and Forecasts to 2027, By Modality (US$ Mn)
                • 9.1.7.2.1 Canada Diagnosis Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.7.2.2 Canada Therapy Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.7.2.3 Canada Imaging Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.7.3 Canada Colorectal Cancer Market Revenue and Forecasts to 2027, By End User (US$ Mn)
              • 9.1.8 Mexico Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
                • 9.1.8.1 Mexico Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
                • 9.1.8.2 Mexico Colorectal Cancer Market Revenue and Forecasts to 2027, By Modality (US$ Mn)
                • 9.1.8.2.1 Mexico Diagnosis Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.8.2.2 Mexico Therapy Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.8.2.3 Mexico Imaging Type Market Revenue and Forecasts to 2027, By Type (US$ Mn)
                • 9.1.8.3 Mexico Colorectal Cancer Market Revenue and Forecasts to 2027, By End User (US$ Mn)

              10. North America Colorectal Cancer Market- Industry Landscape

              • 10.1 Overview
              • 10.2 Growth Strategies In The Colorectal Cancer Market, 2016-2019
              • 10.3 Organic Developments
                • 10.3.1 Overview
                • 10.3.2 Organic Growth Strategies In The Colorectal Cancer Market, 2016-2019
              • 10.4 Inorganic Developments
                • 10.4.1 Overview
                • 10.4.2 Inorganic Growth Strategies In The Colorectal Cancer Market, 2016-2019

              11. Colorectal Cancer Market–Key Company Profiles

              • 11.1 Epigenomics AG
                • 11.1.1 Key Facts
                • 11.1.2 Business Description
                • 11.1.3 Financial Overview
                • 11.1.4 Product Portfolio
                • 11.1.5 SWOT Analysis
                • 11.1.6 Key Developments
              • 11.2 Novigenix SA
                • 11.2.1 Key Facts
                • 11.2.2 Business Description
                • 11.2.3 Financial Overview
                • 11.2.4 Product Portfolio
                • 11.2.5 SWOT Analysis
                • 11.2.6 Key Developments
              • 11.3 Clinical Genomics Technologies Pty Ltd.
                • 11.3.1 Key Facts
                • 11.3.2 Business Description
                • 11.3.3 Financial Overview
                • 11.3.4 Product Portfolio
                • 11.3.5 SWOT Analysis
                • 11.3.6 Key Developments
              • 11.4 EDP Biotech Corporation
                • 11.4.1 Key Facts
                • 11.4.2 Business Description
                • 11.4.3 Financial Overview
                • 11.4.4 Product Portfolio
                • 11.4.5 SWOT Analysis
                • 11.4.6 Key Developments
              • 11.5 Volitionrx Limited
                • 11.5.1 Key Facts
                • 11.5.2 Business Description
                • 11.5.3 Financial Overview
                • 11.5.4 Product Portfolio
                • 11.5.5 SWOT Analysis
                • 11.5.6 Key Developments
              • 11.6 Abbott Laboratories
                • 11.6.1 Key Facts
                • 11.6.2 Business Description
                • 11.6.3 Financial Overview
                • 11.6.4 Product Portfolio
                • 11.6.5 SWOT Analysis
                • 11.6.6 Key Developments
              • 11.7 Amgen Inc.
                • 11.7.1 Key Facts
                • 11.7.2 Business Description
                • 11.7.3 Financial Overview
                • 11.7.4 Product Portfolio
                • 11.7.5 Pipeline (Clinical Trials) Portfolio
                • 11.7.6 SWOT Analysis
                • 11.7.7 Key Developments
              • 11.8 F. Hoffmann-La Roche AG
                • 11.8.1 Key Facts
                • 11.8.2 Business Description
                • 11.8.3 Financial Overview
                • 11.8.4 Product Portfolio
                • 11.8.5 Pipeline (Clinical Trials) Portfolio
                • 11.8.6 SWOT Analysis
                • 11.8.7 Key Developments
              • 11.9 Bruker Corporation
                • 11.9.1 Key Facts
                • 11.9.2 Business Description
                • 11.9.3 Financial Overview
                • 11.9.4 Product Portfolio
                • 11.9.5 SWOT Analysis
                • 11.9.6 Key Developments
              • 11.10 Quest Diagnostics Incorporated
                • 11.10.1 Key Facts
                • 11.10.2 Business Description
                • 11.10.3 Financial Overview
                • 11.10.4 Product Portfolio
                • 11.10.5 SWOT Analysis
                • 11.10.6 Key Developments
              • 11.11 Natera, Inc.
                • 11.11.1 Key Facts
                • 11.11.2 Business Description
                • 11.11.3 Financial Overview
                • 11.11.4 Product Portfolio
                • 11.11.5 SWOT Analysis
                • 11.11.6 Key Developments
              • 11.12 Guardant Health, Inc.
                • 11.12.1 Key Facts
                • 11.12.2 Business Description
                • 11.12.3 Financial Overview
                • 11.12.4 Product Portfolio
                • 11.12.5 SWOT Analysis
                • 11.12.6 Key Developments

              12. Appendix

              • 12.1 About The Insight Partners

      Summary:
      Get latest Market Research Reports on North America Colorectal Cancer . Industry analysis & Market Report on North America Colorectal Cancer is a syndicated market report, published as North America Colorectal Cancer Market to 2027 - Regional Analysis and Forecasts by Modality (Diagnosis Type, Therapy Type, Imaging Type); End User (Hospitals, Diagnostic and Research Laboratories), and Country. It is complete Research Study and Industry Analysis of North America Colorectal Cancer market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,000.00
      $4,000.00
      $5,000.00
      2,397.00
      3,196.00
      3,995.00
      2,799.00
      3,732.00
      4,665.00
      466,650.00
      622,200.00
      777,750.00
      249,990.00
      333,320.00
      416,650.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report